EAGLE PHARMACEUTICALS
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 135
- Market Cap
- $61.6M
- Website
- http://www.eagleus.com
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
4
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 276
- Registration Number
- NCT05776004
- Locations
- 🇺🇸
UCSF Hospital, Fresno, California, United States
🇺🇸UF Health Shands Hospital, Gainesville, Florida, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
- Conditions
- Exertional Heat Stroke
- Interventions
- Other: Standard of Care
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03600376
- Locations
- 🇸🇦
King Faisal Hospital, Mecca, Saudi Arabia
🇸🇦Mina al Jisr Hospital, Mina, Saudi Arabia
🇸🇦Mina Al-Shari Al-Jadeed Hospital, Mina, Saudi Arabia
Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT03324061
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
🇺🇸Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
- Conditions
- Drug Toxicity Psychotropic Agents Psychostimulants
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03189433
- Locations
- 🇺🇸
CrowdRx Medical Office- Moonrise Festival, Baltimore, Maryland, United States
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Eagle Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02513095
- Prev
- 1
- 2
- Next
News
Eagle Pharmaceuticals Secures $69 Million Deal to Monetize BENDEKA Royalties
Eagle Pharmaceuticals has entered into a $69 million royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA, a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma.
FDA Approves PEMFEXY® Combination Therapy for Metastatic Non-Small Cell Lung Cancer
Eagle Pharmaceuticals' PEMFEXY® gains FDA approval for use with pembrolizumab and platinum chemotherapy in metastatic non-squamous NSCLC patients without EGFR or ALK aberrations.
Eagle Pharmaceuticals Submits NDA for Landiolol, Ultra-Short-Acting Beta Blocker for Critical Care Tachycardia
Eagle Pharmaceuticals announced that AOP Orphan Pharmaceuticals submitted a new drug application to the FDA for landiolol, seeking approval for short-term reduction of ventricular rate in patients with supraventricular tachycardia.